Tidal Investments LLC Decreases Holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Tidal Investments LLC reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 67.4% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 13,856 shares of the company’s stock after selling 28,619 shares during the period. Tidal Investments LLC’s holdings in Teva Pharmaceutical Industries were worth $250,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of TEVA. UMB Bank n.a. boosted its position in Teva Pharmaceutical Industries by 555.6% in the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co boosted its holdings in shares of Teva Pharmaceutical Industries by 55.7% in the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at approximately $50,000. Claro Advisors LLC purchased a new stake in Teva Pharmaceutical Industries during the third quarter valued at approximately $52,000. Finally, Mark Sheptoff Financial Planning LLC bought a new position in Teva Pharmaceutical Industries in the second quarter worth approximately $57,000. Institutional investors own 54.05% of the company’s stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the sale, the executive vice president now owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.55% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $22.42 on Thursday. Teva Pharmaceutical Industries Limited has a 52-week low of $10.34 and a 52-week high of $22.50. The company has a market cap of $25.40 billion, a price-to-earnings ratio of -26.38, a PEG ratio of 0.99 and a beta of 0.79. The firm’s fifty day moving average is $17.97 and its 200 day moving average is $17.60. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a research report on Monday, October 21st. Barclays upped their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 18th. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Finally, StockNews.com lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.